These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 1376910

  • 21. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
    Szende B, Srkalovic G, Schally AV, Lapis K, Groot K.
    Cancer; 1990 May 15; 65(10):2279-90. PubMed ID: 1971771
    [Abstract] [Full Text] [Related]

  • 22. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
    Fekete M, Zalatnai A, Schally AV.
    Cancer Lett; 1989 May 15; 45(2):87-91. PubMed ID: 2567204
    [Abstract] [Full Text] [Related]

  • 23. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K.
    Prostate; 2000 Jul 01; 44(2):172-80. PubMed ID: 10881027
    [Abstract] [Full Text] [Related]

  • 24. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B.
    Cancer Res; 1991 Nov 01; 51(21):5980-6. PubMed ID: 1682039
    [Abstract] [Full Text] [Related]

  • 25. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
    Szende B, Zalatnai A, Schally AV.
    Proc Natl Acad Sci U S A; 1989 Mar 01; 86(5):1643-7. PubMed ID: 2564204
    [Abstract] [Full Text] [Related]

  • 26. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV, Kook AI, Monje E, Redding TW, Paz-Bouza JI.
    Proc Natl Acad Sci U S A; 1986 Nov 01; 83(22):8764-8. PubMed ID: 2946045
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
    Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Jul 19; 91(15):7090-4. PubMed ID: 7518926
    [Abstract] [Full Text] [Related]

  • 28. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.
    Fekete M, Redding TW, Comaru-Schally AM, Pontes JE, Connelly RW, Srkalovic G, Schally AV.
    Prostate; 1989 Jul 19; 14(3):191-208. PubMed ID: 2471961
    [Abstract] [Full Text] [Related]

  • 29. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
    Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai RZ, Szepeshazi K, Radulovic S.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):1061-7. PubMed ID: 1981009
    [Abstract] [Full Text] [Related]

  • 30. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Int J Cancer; 1994 Oct 01; 59(1):51-5. PubMed ID: 7927904
    [Abstract] [Full Text] [Related]

  • 31. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    Zalatnai A, Paz-Bouza JI, Redding TW, Schally AV.
    Prostate; 1988 Oct 01; 12(1):85-98. PubMed ID: 2894651
    [Abstract] [Full Text] [Related]

  • 32. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T.
    Acta Oncol; 1994 Oct 01; 33(6):693-701. PubMed ID: 7946450
    [Abstract] [Full Text] [Related]

  • 33. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T, Redding TW, Ben-David M, Schally AV.
    Proc Natl Acad Sci U S A; 1988 Feb 01; 85(3):890-4. PubMed ID: 2893378
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM.
    Cancer Lett; 2001 Sep 28; 171(1):37-45. PubMed ID: 11485826
    [Abstract] [Full Text] [Related]

  • 35. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 36. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
    Szepeshazi K, Lapis K, Schally AV.
    Int J Cancer; 1991 Sep 09; 49(2):260-6. PubMed ID: 1679045
    [Abstract] [Full Text] [Related]

  • 37. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
    Lamharzi N, Halmos G, Jungwirth A, Schally AV.
    Int J Oncol; 1998 Sep 09; 13(3):429-35. PubMed ID: 9683774
    [Abstract] [Full Text] [Related]

  • 38. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K.
    Cancer Res; 1994 Nov 15; 54(22):5895-901. PubMed ID: 7954420
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
    Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV.
    Breast Cancer Res Treat; 1992 Nov 15; 21(1):35-45. PubMed ID: 1391973
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL.
    Prostate; 2002 Aug 01; 52(3):173-82. PubMed ID: 12111694
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.